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The antiprotozoal drug pentamidine [1,5-bis(4'-amidinophenoxy)pentaneI has been previously shown to be
metabolized by rat liver microsomes, and five of the seven putative primary metabolites have been identified.
With the synthesis and identification of 5-(4'-amidinophenoxy)pentanoic acid and 5-(4'-amidinophenoxy)-1-
pentanol as the remaining two metabolites, the primary metabolism of pentamidine in rats appears fully
characterized. Use of [14C]pentamidine with rat liver microsomes confirms this conclusion, since no
unidentified radioactive peaks were detected by high-performance liquid chromatography (HPLC). Isolated,
perfused rat livers were used with [14C]pentamidine to identify secondary metabolites. Only two novel
radioactive peaks were detected by HPLC analysis of perfused liver samples. The treatment of liver samples
with sulfatase or 13-glucuronidase resulted in the reduction or elimination of these peaks and gave rise to peaks
identified as para-hydroxybenzamidine and 5-(4'-amidinophenoxy)pentanoic acid. It was concluded from these
results that only these two primary metabolites were conijugated with sulfate or glucuronic acid. After 4 h of
incubation in the perfused liver system, approximately 15% of the recovered radiolabel was pentamidine.
These results suggest that pentamidine metabolism can be rapid and extensive in rats.
Pentamidine [1,5-bis(4'-amidinophenoxy)pentane] has been
used for decades in the prophylaxis and treatment of African
trypanosomiasis and treatment of antimony-resistant leishma-
niasis and Pneumocystis carinii pneumonia (11, 20). The
increased incidence of P. carini pneumonia associated with
the AIDS epidemic has brought about an increase in the
clinical use of pentamidine in North America (15). Despite
several early studies of the pharmacological properties of the
drug (14, 16, 17, 22, 23), little was known about the com-
pound. With the development of sensitive and accurate high-
performance liquid chromatography (HPLC) assays (1, 9, 18),
more detailed studies on the distribution and pharmacokinet-
ics of pentamidine have been conducted (2, 7, 8). However,
these studies have been performed with the misconception
that pentamidine is metabolically inert, a conclusion primarily
based on the work of Launoy et al. (16, 17).
We have previously demonstrated that pentamidine is
readily converted to seven putative metabolites by rat liver
microsomes (3, 4). Five of the seven primary metabolites
have been identified as hydroxylated derivatives of the
parent compound (see Fig. 1). The cytochrome P-450-depen-
dent mixed-function oxidases have been identified as the
enzyme system responsible for this activity (3). In this
paper, we describe the characterization of the two remaining
primary metabolites of pentamidine. In addition, isolated,
perfused rat livers were used to determine the secondary
metabolic pathways and to determine the extent of pentami-
dine metabolism in a model in which both primary and
secondary metabolic systems were active.
MATERIALS AND METHODS
Compounds. Pentamidine isethionate was obtained from
Fujisawa USA, Inc. (Rosemont, Ill.), and ['4C]pentamidine
(labelled in the amidino carbons; 32 mCi/mmol) was gra-
* Corresponding author.
ciously provided by the National Institutes of Health (Be-
thesda, Md.). NADPH tetrasodium salt, 1-heptane sulfonic
acid sodium salt, glucose-6-phosphate, glucose-6-phosphate
dehydrogenase, saccharic lactone, sulfatase, and 1-gluc-
uronidase were acquired from Sigma Chemical Co. (St.
Louis, Mo.), and tetramethyl ammonium chloride and
HPLC-grade acetonitrile were obtained from Fisher Scien-
tific Co. (Fair Lawn, N.J.). All water was deionized and
filtered by a water purification system (Darco, Durham,
N.C.). The structures of all pentamidine metabolites are
shown in Fig. 1.
Synthesis of 5-(4'-amidinophenoxy)pentanoic acid. A solu-
tion of 5-bromovaleric acid (Aldrich Chemical Co., Milwau-
kee, Wis.) (6.0 g, 0.03 mol) in absolute ethanol (150 ml) and
a few drops of H2SO4 was heated under reflux for 24 h. The
ethanol was removed under a vacuum to afford 6.7 g (97%) of
ethyl-5-bromo-pentanoate as an oil. Sodium (0.63 g, 27.5
mmol) was dissolved in absolute ethanol (20 ml), and 4-cy-
anophenol (3.0 g, 25 mmol) was added. The solution was
heated at reflux for 30 min before ethyl-5-bromo-pentanoate
(6.67 g, 32 mmol) in absolute ethanol (10 ml) was added and
the solution was heated under reflux for 60 h. The ethanol
was removed under reduced pressure, and the resulting
ethyl-5-(4'-cyanophenoxy)pentanoate was recrystallized
from ethanol-H20 to afford 4.5 g (73%) of the desired
product as a white solid.
A suspension of ethyl-5-(4'-cyanophenoxy)pentanoate
(2.0 g, 8.1 mmol) in dry dioxane (100 ml) and dry methanol (2
ml) was chilled to 5°C, and the solution was saturated with
HCI (gas) for 1.5 h, with the temperature maintained below
10°C. The flask was stoppered, and the reaction mixture was
stirred at room temperature for 9 days. During this time, the
solution was resaturated twice and additional methanol (4
ml) was added. After an infrared spectrum indicated that the
nitrile had disappeared, the dioxane was removed under
reduced pressure and the resulting white solid was sus-
pended in anhydrous diethyl ether and collected by filtration.
This imidate was immediately suspended in anhydrous meth-
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FIG. 1. Metabolism of pentamidine. Compounds: I, 1,5-bis(4'-amidinophenoxy)-3-pentanol; II, 1,5-di(4'-amidinophenoxy)-2-pentanol; III,
1,5-di(4'-amidinophenoxy)-l-pentanol; IV, para-hydroxybenzamidine; V, 5-(4'-amidinophenoxy)-l-pentanal; VI, 1-(4'-hydroxyamidinophe-
noxy)-5-(4'-amidinophenoxy)pentane; VII, 1,5-bis(4'-hydroxyamidinophenoxy)pentane; VIII, 5-(4'-amidinophenoxy)pentanoic acid; IX,
5-(4'-amidinophenoxy)-1-pentanol. Brackets and asterisks indicate that compounds III and V have not been isolated.
anol saturated with ammonia (75 ml), the flask was stop-
pered, and the solution was heated to an oil bath temperature
of 80°C for 6 h. The heat was removed, and the solution was
stirred at room temperature for 18 h. The solvent was
removed under reduced pressure, and the resulting solid was
dissolved in 2 N HCl (50 ml) and heated at reflux for 22 h.
The solution was cooled to room temperature, and the solid
was removed by filtration. The product remained predomi-
nantly in the aqueous solution, so the solvent was removed
under reduced pressure to afford 482 mg of the desired
product. The solid collected by filtration was heated with
additional water and filtered while hot. Removal of the
solvent under reduced pressure yielded 455 mg of additional
product for a total of 937 mg (42%) of 5-(4'-amidinophenox-
y)pentanoic acid. The melting point was 219 to 221°C.
Nuclear magnetic resonance (90 MHz, dimethyl sulfoxide-
d6) 1.7 (m, 4H, internal CH2CH2); 2.25 (t, 2H, CH2CO); 4.2
(t, 2H, CH2O); 7.2 (d, 2H, Ar-H); 7.9 (d, 2H, Ar-H); 9.3 (d,
4H, Am-H). Elemental analysis was calculated for
C12H16N203. HCl. Calculated: C, 52.84; H, 6.28; N, 10.27.
Found: C, 52.75; H, 6.33; N, 10.17.
Synthesis of 5-(4'-amidinophenoxy)-1-pentanol. Sodium
(0.43 g, 18.5 mmol) was dissolved in dry ethanol (15 ml), and
4-cyanophenol (Aldrich Chemical Co.) (2.0 g, 16.8 mmol) in
ethanol (5 ml) was added. The solution was heated under
reflux for 30 min. 5-Bromo-1-pentene (4.0 ml, 5.0 g, 33.6
mmol) was added, and the reflux was continued for 40 h. The
solution was cooled on an ice bath, and the inorganic
material was removed by filtration and washed with methyl-
ene chloride. The methylene chloride was extracted several
times with 15% NaOH to remove residual starting phenol.
The ethanol and methylene chloride were combined and
dried with MgSO4. The drying agent was removed by
filtration, and the mother liquor was evaporated to dryness
to afford an oil. The oil was chromatographed on silica gel
(80 g) by elution with chloroform. The appropriate fractions
were combined, and the solvent was removed under reduced
pressure to yield 2.4 g (78%) of 5-(4'-cyanophenoxy)-1-
pentene. A solution of 5-(4'-cyanophenoxy)-1-pentene (2.5
g, 13.4 mmol) in dry tetrahydrofuran (50 ml) was chilled to
0°C in dry glassware under N2. BH3 (1.0 M) in tetrahy-
drofuran (6.7 ml) was added dropwise via a syringe at a rate
sufficient to maintain the low temperature. After the addition
was complete, the solution was allowed to warm to room
temperature and was stirred at room temperature for 3 h.
Water (0.75 ml) was added slowly, the solution was chilled to
0°C, and 3.0 M NaOH (2.5 ml) was added all at once. The
reaction mixture was warmed to room temperature, and 30%
H202 was added at a rate that maintained the temperature of
the reaction mixture below 40°C. After the addition was
complete, the reaction mixture was warmed to 50°C for 1 h.
The reaction mixture was cooled to room temperature, and
the tetrahydrofuran was washed with H20 (25 ml). The H20
was extracted with diethyl ether (three 25-ml portions), and
the organic fractions were combined and dried (MgSO4). The
inorganic material was removed by filtration, and the sol-
vents were removed in vacuo to afford 3.1 g of impure
material. The compound was purified by centrifugal chroma-
tography by elution from silica gel plates with 4:1 ethyl
acetate-hexanes. The appropriate fractions were combined,
and the solvents were removed under reduced pressure to
yield 2.35 g (85%) of 5-(4'-cyanophenoxy)-1-pentanol as a
clear oil.
A solution of 5-(4'-cyanophenoxy)-1-pentanol (1.93 g, 9.4
mmol) in dry dioxane (100 ml) and methanol (2 ml) was
cooled on an ice bath to a temperature of 10°C. The solution
Glucuronidation
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was saturated with HCl (gas) for 1 h. The flask was stop-
pered, and the solution was stirred at room temperature for
20 h. The dioxane was removed in vacuo, and the resulting
solid was stirred with diethyl ether and collected by filtration
under N2. The solid was dissolved in ethanol saturated with
NH3 (100 ml), the flask was stoppered, and the solution was
heated to an oil bath temperature of 80°C for 6 h. The
solution was stirred at room temperature for 14 h. The
ethanol was removed under reduced pressure to afford 1.0 g
(41%) of 5-(4'-amidinophenoxy)-1-pentanol. The melting
point was 178 to 182°C. Nuclear magnetic resonance (300
MHz, dimethyl sulfoxide-d6) 1.4 to 1.6 (m, 4H, HO-CH2CH,
ArO-CH2CH2); 1.75 (q, 2H, internal CH2); 3.43 (t, 2H,
HOCH2); 4.08 (t, 2H, ArO ); 4.4 (br s, 1H, HO); 7.15
(d, 2H, Ar-H); 7.83 (d, 2H, Ar-H); 8.98 (s, 2H, Am-H); 9.21
(s, 2H, Am-H). Elemental analysis was calculated for
C12H18N202. HCl. Calculated: C, 55.70; H, 7.40; N, 10.83.
Found: C, 55.71; H, 7.45; N, 10.74.
Preparation of microsomes. Male, barrier-raised Sprague-
Dawley rats (Hilltop Lab Animals, Inc., Scottsdale, Pa.)
were housed in a controlled environment with a 12-h light-
12-h dark cycle and allowed free access to rat chow (Agway,
Syracuse, N.Y.) and tap water. All food was removed 24 h
before the animals were sacrificed by decapitation. The
livers were excised immediately, rinsed with 50 mM phos-
phate (KH2PO4-K2HPO4) buffer (pH 7.4), and placed on ice.
All subsequent steps were performed at 4°C. The livers were
minced with scissors and homogenized with 2 volumes of 50
mM phosphate buffer (pH 7.4) with a Teflon pestle-glass tube
homogenizer (A. H. Thomas Co., Philadelphia, Pa.). The
homogenates were centrifuged at 9,000 x g for 20 min, and
the supernatant was subsequently centrifuged at 100,000 x g
for 60 min. The resulting microsomal pellet was resuspended
in 50 mM phosphate buffer (pH 7.4).
Incubation and assay system. One milliliter of microsomal
preparation was added to 3 ml of phosphate buffer (pH 7.4)
and 1 ml of cofactor solution (2 mg ofNADPH per ml, 1.3 mg
of glucose-6-phosphate per ml, and 0.1 U of glucose-6-
phosphate dehydrogenase per ml in phosphate buffer [pH
7.4]) and preincubated for 1 to 2 min at 37°C in a shaking
water bath. One milliliter of pentamidine or [14C]pentami-
dine (various concentrations) in phosphate buffer (pH 7.4)
was added to start the incubation. The reactions were
terminated by placement on ice.
Routine analysis of samples was performed as described
by Berger et al. (3, 4). Briefly, a Hewlett-Packard 1090 or
1084B liquid chromatograph (Hewlett-Packard, Avondale,
Pa.) was used with a Zorbax RX diisopropyl C-8 column (25
cm by 4.6 mm) (Mac-Mod Analytical, Chadds Ford, Pa.)
kept at 40°C. Elution was performed with a gradient of 3.75
to 45% CH3CN (in 10 mM heptane sulfonate-10 mM tetra-
methylammonium chloride-4.2 mM H3PO4-H2O) over 30
min. Detection was by UV spectrophotometry at 265 nm.
This assay was sensitive to 1 ng of pentamidine per ml and
was linear over the entire range of concentrations analyzed.
The assay had an error of less than 5% on inter- and intraday
analyses. Coelution of synthesized metabolites with sus-
pected metabolite peaks from pentamidine incubations was
detected by using the Zorbax RX column, the Supelco
DB-C18 column (Supelco, Bellefonte, Pa.), the Keystone
Scientific Hypersil2 phenyl column, and the Keystone Sci-
entific Hypersil2 cyano column (Keystone Scientific, Belle-
fonte, Pa.) as described by Berger et al. (4).
Initially, samples were extracted over Prep-Sep C-18 solid
phase extraction cartridges (Fisher Chemical Co., Fair
Lawn, N.J.) prior to HPLC analysis (1). However, higher
overall recovery was obtained through direct injection of
microsomal incubations onto the HPLC. An in-line filter unit
(Rheodyne 7335 inlet filter; Rheodyne, Cotati, Calif.) was
used to protect the column from the increased particle load.
When microsomal samples were incubated with ["4C]pen-
tamidine, 30-s fractions (0.75 ml) were collected from the
HPLC after passing through the UV spectrophotometric
detector. Aliquots of 200 ,ul from each fraction were then
added to 3 ml of Cyto-Scint scintillation fluid (ICN Biomed-
icals, Costa Mesa, Calif.) and placed in a Beckman LS 7000
scintillation counter (Beckman, Norcross, Ga.) for measure-
ment.
Isolated, perfused rat liver incubations. Male, viral-anti-
gen-free, Sprague-Dawley rats (250 to 275 g) (Charles River,
Kingston, N.Y.) were housed in well-ventilated cages and
kept at 24 + 2°C with 40 to 60% humidity while on a regular
12-h light-dark cycle for a minimum of 14 days before
experiments. They were fed ad libitum on standard rat chow
and tap water. At all times during this study, pain to animals
was minimized through the use of anesthesia and analgesia.
Rats were anesthetized with ketamine (40 mg per kg of
body weight) and xylazine (5 mg/kg) by intraperitoneal
injection, and their livers were isolated according to a
standard technique with modifications (19). The liver was
placed on a glass platform inside a thermostatically con-
trolled (37 ± 0.1°C) perfusion cabinet. Livers were perfused
with Krebs bicarbonate buffer solution containing 20% fresh
(1- to 5-day-old), washed sheep erythrocytes, 1% bovine
serum albumin, and 0.1% glucose. This buffer was recircu-
lated from a central reservoir by a roller pump (Minipuls-2;
Gilson Int.) in a closed system, at a perfusion rate of 1.5 ml/g
of liver weight per min. Prior to each experiment, all
glassware and tubing were silanized with Aquasil (Pierce,
Rockford, Ill.). Sodium taurocholate (30 ,umol/h) was con-
tinuously infused (Syringe Infusion Pump no. 22; Harvard
Apparatus) throughout the experiment to simulate enterohe-
patic bile acid cycling and to normalize the composition of
bile (25). The perfusate was oxygenated with a mixture of
humidified 02-CO2 (95/5) which was passed through an
artificial lung composed of Silastic tubing (Dow Corning,
Midland, Mich.). The perfusate pH was continuously mon-
itored with a Radiometer ETS811,822 endpoint titration
system (Radiometer, Copenhagen, Denmark), which main-
tained the pH at 7.4 ± 0.02 with sodium bicarbonate (2.5 M).
Perfusate partial pressures Of 02 and CO2 were measured
with a Corning 168 blood gas analyzer at the beginning and
end of each experiment. All experiments were performed
after a 20-min stabilization period. The principal indices of
liver viability were steady oxygen consumption (21), sus-
tained bile production (6), stable potassium and alanine
aminotransferase activity (12), stable pH, a portal pressure
of less than 8 cm of H20, and normal visual appearance.
The metabolism and distribution of [14C]pentamidine in
the liver were studied for 4 h after a 5-mg/kg bolus injection
(n = 4). Labelled pentamidine (diluted with radioinert pent-
amidine to a specific activity of 27 ,uCi/mg) was added
directly to the reservoir as a 5-mg/ml solution in saline.
Samples (1 ml) were removed from the perfusate reservoir
predose and at 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 150, 180,
210, and 240 min postdose. The sample volume was replaced
with an equal volume of fresh perfusate added directly to the
reservoir. After centrifugation (1,100 x g for 3 min), the
perfusate plasma was separated and stored at -70°C until it
was assayed for pentamidine, its metabolites, and radioac-
tivity. Bile was collected into preweighed vials at 30, 60, 90,
120, 150, 180, 210, and 240 min after the dose. The bile
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volume was determined by weight (assuming a density of 1.0
g/ml) and stored at -70°C. The whole liver from each
experiment was stored at -70°C until homogenization and
fractionation.
Binding of the drug to the perfusion apparatus was evalu-
ated after each experiment. The perfusate was pumped from
the apparatus, and all glassware was washed with normal
saline (twice), sodium hypochlorite solution, and methanol
by forced syringe irrigation. Each washing solution was
separately recirculated through the apparatus for 20 min.
Samples of each type of tubing and of each of the washes
were taken pre- and postperfusion for determination of
radioactivity not removed by the washes.
Radioactivity was measured with a Packard 2500 liquid
scintillation counter with correction for chemiluminescence
and quench. Samples of whole perfusate, perfusate plasma,
and washes (100 ,ul each) and tubing (3 cm) and bile (25 pl)
were incubated with 600 p,l of 30% H202 and 300 ,ul of 70%
perchloric acid in a heated (60°C) water bath for 4 h.
Scintillation fluid (10 ml) was added, and samples were
cooled overnight and then assayed for radioactivity. Sam-
ples of whole liver homogenate and subsequent fractions
were solubilized and decolorized as described above before
being assayed for radioactivity.
Analysis of radioactive rat liver samples. Aliquots of sam-
ples from the isolated, perfused rat liver incubations were
analyzed by HPLC with photodiode array UV and radiomet-
ric detection. The column (Zorbax RX), buffers, and run
conditions were as described above for the microsomal
HPLC method, with the column connected to a Waters 6000
solvent delivery system (Waters, Milford, Mass.) controlled
by a Waters Expert Ease 860 operating system. A Waters
temperature control system was used to keep the column at
40°C, and samples were injected by the Waters WISP 710
autoinjector. Effluent from the column passed through a
Hewlett-Packard 1040 photodiode array detector controlled
by the Hewlett-Packard Chemstation operating system. This
detector scanned 180 to 400 nm every 640 ms. The effluent
from the photodiode array detector then passed through a
Ramona LS liquid cell radiochemical detector (Service Cor-
poration, Fairfield, N.J.) with Hydrofluor (National Diag-
nostics, Manville, N.J.) liquid scintillation fluid.
Identification of secondary metabolites. The bile samples
collected from the isolated, perfused rat livers were used to
characterize conjugated metabolites. Aliquots of 200 ,lI from
each of the bile samples were mixed with 400 pl of either 0.2
M acetate buffer (pH 5), 2,500-U/ml ,3-glucuronidase in 0.2
M acetate buffer (pH 5), or 660-U/ml sulfatase in 0.2 M
acetate buffer (pH 5). Saccharic lactone (20 mM) was added
to the stock sulfatase solution to inhibit any contaminating
,-glucuronidase activity. The samples were then incubated
at 37°C for 7 h in a shaking water bath. Portions of each
sample were then analyzed by the radioactive HPLC method
described above.
RESULTS
Identification of primary metabolites. A chromatogram
from the HPLC analysis of a 1-h incubation of pentamidine
with rat liver microsomes is shown in Fig. 2. The peaks
labelled a to g are the putative metabolites of pentamidine
(peak p). Peaks a, d, e, f, and g have been previously
identified as compounds IV (Fig. 1), I, II, VII, and VI,
respectively (3, 4). Since metabolite IV likely resulted from
hydroxylation of pentamidine at the carbon adjacent to the





FIG. 2. Chromatogram of a microsomal pentamidine incubation.
Pentamidine (0.17 mM) was incubated with rat liver microsomes for
1 h at 37°C. HPLC analysis was as described in Materials and
Methods. Labelled peaks: a, para-hydroxybenzamidine (IV); b and
c, unidentified metabolites; d, 1,5-bis(4'-amidinophenoxy)-3-pen-
tanol (I); e, 1,5-di(4'-amidinophenoxy)-2-pentanol (II); f, 1,5-bis(4'-
hydroxyamidinophenoxy)pentane (VII); g, 1-(4'-hydroxyamidi-
nophenoxy)-5-(4'-amidinophenoxy)pentane (VI); p, pentamidine.
moiety, it was possible that the two unidentified metabolite
peaks (b and c in Fig. 2) represented the remaining portion of
the molecule. For this reason, attempts to synthesize com-
pound V and its two potential conversion products, VIII and
IX, were made.
The last two compounds were synthesized and found to
coelute with the two unidentified metabolite peaks as shown
in Fig. 3. The coelution analyses were also performed on
three other columns (octadecyl silane, phenyl silane, and
cyano silane), and the two compounds were found to coelute
in each case. These results strongly indicate that the remain-
ing two primary metabolites of pentamidine are compounds
VIII and IX.
Mass balance of microsomal metabolism. [14C]pentamidine
was used with rat liver microsomes to determine whether the
seven metabolites identified to date accounted for the en-
tirety of the primary metabolism of the drug. Preliminary
experiments were performed to quantify the losses during
the C-18 extraction process by monitoring the extraction of
a [14C]pentamidine incubation. Of the starting radioactivity,
69% was recovered in the eluate and 31% was recovered
elsewhere (5% during loading, 1% in the CH3CN wash, 2%
in the H20 wash, and 23% bound to the cartridge itself).
Since a significant portion of the parent compound and its
metabolites could be lost by extraction, samples were no
longer subjected to C-18 extraction and were directly in-
jected onto the HPLC. Table 1 shows the results of two
different [14C]pentamidine incubations with the same prepa-
ration of rat liver microsomes as the enzyme source. The
samples were analyzed by HPLC followed by liquid scintil-
lation of 30-s fractions collected from the column. While
2.5% of the total radioactivity was found as background
(low-level radioactivity found in all the fractions), no addi-
1828 BERGER ET AL.
METABOLISM OF PENTAMIDINE 1829
A
c~~~~~~~
FIG. 3. Coelution of compounds VIII and IX with metabolite
peaks. Pentamidine (0.17 mM) was incubated with rat liver mi-
crosomes for 1 h at 37°C and analyzed by HPLC as described in
Materials and Methods. (A) Chromatogram of the, pentamidine
incubation; (B) chromatogram of a sample of the same incubation
with synthesized compound IX added immediately before injection;
(C) chromatogram of the same incubation with synthesized com-
pound VIII added immediately before injection. Arrows indicate the
peaks increased by adding standard compounds.
tional radioactive peaks beyond those associated with pent-
amidine and its known metabolites were discovered. There-
fore, it is unlikely that there are any remaining unidentified
primary metabolites of pentamidine.
Secondary metabolism of pentamidine. After determination
of the primary metabolism of pentamidine, it was important
to determine whether the primary metabolites were further
metabolized. To accomplish this aim, [14C]pentamidine was
added to the perfusate of the isolated, perfused rat liver
system. Under these conditions, for a period of 4 h, the drug
was subject to active primary and secondary metabolic
enzymes. By comparing chromatograms of bile or perfusate
from the livers to chromatograms of microsomal incuba-
tions, it is possible to identify novel HPLC peaks that may
be conjugated metabolites. Analysis of samples from per-







FIG. 4. Identification of secondary metabolites in a bile sample.
['4C]pentamidine (5 mg/kg) was recirculated in isolated, perfused rat
livers, and 30-min bile samples were collected for 4 h. The bile from
three livers was pooled to create composite samples, and aliquots
from each time point were analyzed by HPLC-radiochemical detec-
tion as described in Materials and Methods. The chromatograms
shown are from the 180- to 210-min composite bile sample. Samples
of 200 ,ul of bile and 400 pl of either acetate buffer alone (control)
(A), ,3-glucuronidase in acetate buffer (B), or sulfatase in acetate
buffer (C) were incubated for 7 h at 37°C. Labelled peaks: x and y,
secondary metabolites; a, compound IV; b, compound VIII; c,
compound IX; d, compounds I and II; p, pentamidine compounds 6
and 7.
both bile and perfusate (Fig. 4A). Preincubation of the
samples with sulfatase or ,B-glucuronidase decreased or
eliminated these peaks (Fig. 4B and C). The conjugate peaks
detected (peaks x and y in Fig. 4) appear to be mixtures of
sulfate and glucuronide conjugates. As these conjugate
peaks decreased, there was a corresponding increase in the
peaks associated with metabolites IV and VIII. In all the
samples analyzed (bile, perfusate, and liver fractions), only
these two primary metabolites appeared to be conjugated.
Bile and perfusate samples were collected every 30 min for
4 h and were analyzed by HPLC after treatment with
,B-glucuronidase or sulfatase. As shown in Fig. 5, approxi-
mately 90% of the dosed pentamidine is rapidly cleared from
the perfusate. A small portion of the radiolabel is detected in
the bile samples over time, but it appears that the majority of
the radioactivity remains in the liver. Figure 6 shows the
relative excretion of conjugates and intact pentamidine in the
TABLE 1. Metabolism of pentamidine by rat liver microsomes
dpma % of recovered radiolabel identified as:
Sample Pentamidine Incubationconcn (mM) time (h) Injected Recovered Pentamidine I + 11 VIII + IX IV Background
+ VI + VII aiatvt
1 0.13 4 5.35 x 107 5.23 x 107 85.08 11.32 0.70 0.55 2.35
2 0.03 2 1.07 x 107 1.55 x 107 69.46 26.14 0.81 0.89 2.70

















FIG. 5. Uptake of pentamidine by perfused livers. ["4C]pentami-
dine (5 mg/kg) was injected into isolated, perfused rat livers, and
perfusate and bile samples were collected periodically. Both bile and
perfusate samples were analyzed for radiolabel content by liquid
scintillation as described in Materials and Methods. Squares, per-
fusate radioactivity; circles, bile radioactivity. Bars, standard devi-
ations.
bile over time. Almost immediately, pentamidine is found in
the bile, and its concentration drops over time as the
concentration of conjugates excreted rises. The concentra-
tions of primary metabolites in bile also rose over time (data
not shown).
Metabolism in isolated, perfused rat livers. In addition to
identifying potential secondary metabolites, use of the iso-
lated, perfused rat liver allows a more complete model of
metabolism than microsomes without the complications as-
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FIG. 6. Excretion of pentamidine and conjugated metabolites in
rat bile. ['4C]pentamidine (5 mg/kg) was injected into isolated,
perfused rat livers, and 30-min bile samples were collected. The
individual bile samples were analyzed by HPLC-radiochemical
detection as described in Materials and Methods. Lines show the
relative percentage of biliary radioactivity present as pentamidine
(open squares) or conjugated metabolites (closed squares).
several perfused livers (n = 4) were analyzed by HPLC to
determine the overall metabolism of pentamidine. The per-
centages of the radiolabel recovered from the analyzed
fractions were as follows: bile, 5.39 + 0.45; perfusate, 11.17
± 1.35; liver pellet (9,000 x g), 35.28 ± 8.78; liver superna-
tant (100,000 x g), 19.40 ± 1.29; and liver pellet (100,000 x
g), 12.15 ± 2.70. (Values are averages ± standard deviations
for four livers.) The overall recovery of the radiolabel was
high (87.85% ± 10.06%), and most of the radioactivity was
associated with liver samples, rather than with bile or
perfusate. Sample loss due to binding to the perfusion
apparatus was very low (approximately 3.5%).
Pentamidine is extensively metabolized in this model, with
only 15% of the recovered radiolabel being the parent
compound. In the recovered radiolabel, the percentages of
various compounds found were as follows: pentamidine plus
compound VI plus compound VII, 15.46 ± 3.04; compound
I plus compound II, 61.75 ± 5.14; compound VII plus
compound IX, 0.47 ± 0.16; and compound IV, 6.80 ± 3.50.
(Values are averages ± standard deviations for four livers.)
The majority of the radioactivity was recovered as metabo-
lites I and II, and a significant proportion of the radiolabel
(15.49% ± 1.69%) was detected as conjugated metabolites.
Therefore, pentamidine can be rapidly metabolized by rat
livers. No radioactive peaks which did not correspond to the
known primary metabolites or to the conjugates of com-
pounds IV and VIII were detected in these livers.
DISCUSSION
Pentamidine has been widely reported to be metabolically
inert (5, 10, 11, 13, 20), partly on the basis of interpretations
of research conducted by Launoy et al. (16, 17) and Waalkes
et al. (22). However, in this study and in previous work (3,
4), we have demonstrated that pentamidine can be rapidly
and extensively metabolized by the rat cytochrome P450,
glucuronyl transferases, and sulfotransferases. Figure 1
summarizes the metabolic pathway of pentamidine. In rats,
the two major metabolites (quantitatively) are compounds I
and II, which do not appear to be conjugated with glucuronic
acid or sulfate. Studies conducted with [14C]pentamidine in
isolated, perfused livers and with rat liver microsomes seem
to confirm that the scheme proposed in Fig. 1 represents the
complete metabolism of pentamidine, since no radioactive
peaks which do not correspond to a known metabolite were
found by HPLC. It is possible, though unlikely, that other
metabolites may coelute with the identified compounds. To
date, we have not been able to synthesize compounds III and
V.
Knowledge of the metabolic transformation of pentami-
dine leads to several questions, all of which are currently
under investigation. Most important are the toxicity and
antimicrobial activities of each of the metabolites, since
pentamidine is utilized clinically and is quite toxic (15). More
than 50% of all patients suffer from adverse effects, ranging
from mild neutropenia to severe nephrotoxicity (24). We
have previously demonstrated that N-hydroxylation of pen-
tamidine leads to a drop in antimicrobial activity (3), and the
remaining primary metabolites are currently being tested in a
similar manner. Therefore, it will soon be determined
whether pentamidine metabolism is an activating or a deac-
tivating system with respect to toxicity and antimicrobial
effectiveness.
Another important question relates to comparative meta-
bolic studies. All work to date has been performed with rats,
and there is no knowledge as to the potential pathways in
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other species, particularly humans. We are presently inten-
sively studying the metabolism of pentamidine in mice,
rabbits, and humans. Finally, we reported (4) that the
cytochrome(s) P-450 responsible for pentamidine metabo-
lism in rats was not inducible by seven different compounds.
We are presently involved in purifying and identifying the
pentamidine hydroxylase from rat liver and determining
whether the same isozyme is responsible for pentamidine
hydroxylation in mouse and rabbit liver and lung tissue.
There is a great need for better compounds in the treat-
ment of P. carinii pneumonia and African trypanosomiasis.
Knowledge of pentamidine metabolism, its effect on toxicity
and antimicrobial activity, and its enzymology will play a
large role in the rational development of improved analogs
for clinical use.
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